LINC01587: A Drug Target / Disease Biomarker (G10141)

Target Name: LINC01587

NCBI ID: G10141

LINC01587

LINC01587: A Drug Target / Disease Biomarker

LINC01587 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and its potential as a drug have piqued the interest of pharmaceutical companies.

LINC01587 is a long non-coding RNA molecule that is approximately 240 amino acids in length. It is expressed in various tissues and cells of the body and has been shown to play a role in various biological processes, including cell signaling, tissue repair, and inflammation.

One of the key features of LINC01587 is its expression patterns. It is highly expressed in the liver, kidneys, and heart, and is also expressed in various other tissues and cells, including the brain, pancreas, and gastrointestinal tract. This suggests that it may be a potential drug target that can be targeted by small molecules or other therapeutic agents specifically designed to modulate its expression.

Another feature that has made LINC01587 an attractive target for drug research is its unique structure. Unlike many other non-coding RNAs, LINC01587 has a well- conserved open reading frame (ORF) and a stable structure that allows it to form a stable complex with various transcription factors. This stability has been shown to play a role in the regulation of various gene expression pathways and has led to the conclusion that LINC01587 may be a good candidate for drugs that can specifically modulate its expression levels.

In addition to its expression patterns and unique structure, LINC01587 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that LINC01587 is highly expressed in various types of cancer and that its expression is associated with the development of these diseases. This suggests that LINC01587 may be a potential biomarker for cancer and that its expression levels may be a useful target for diagnostic or therapeutic interventions.

Despite the potential benefits of LINC01587 as a drug target and biomarker, there are also some challenges that must be overcome before it can be fully developed as a therapeutic agent. One of the main challenges is the difficulty of predicting the exact mechanism of action of LINC01587 as a drug. While its unique structure and expression patterns have made it an attractive target for study, it is still not clear exactly how it interacts with its cognate proteins and how these interactions will translate into its biological effects.

Another challenge is the difficulty of finding small molecules or other therapeutic agents that can specifically modulate LINC01587's expression levels. While LINC01587 is a well- conserved molecule with a well- conserved ORF, it is still a relatively small molecule and finding small molecules that can specifically interact with it may be challenging.

Despite these challenges, the potential benefits of LINC01587 as a drug target and biomarker are too great to ignore. As research continues to advance, the full potential of LINC01587 as a therapeutic agent may become clearer and its development as a new drug may finally become a reality.

In conclusion, LINC01587 is a non-coding RNA molecule that has the potential to be a drug target and biomarker for various diseases. Its unique structure and expression patterns, as well as its association with the development of various diseases, make it an attractive target for research and development. While there are still many challenges that must be overcome, the potential benefits of LINC01587 make it a promising molecule for further study and potential therapeutic intervention.

Protein Name: Long Intergenic Non-protein Coding RNA 1587

The "LINC01587 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01587 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets